Viking Therapeutics targets Phase 3 trials for VK2735 in Q2 2025 amid strong clinical progress
Viking plans to explore monthly dosing for ... for weight loss in the ongoing VENTURE trial for oral VK2735. Brian Lian ...
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial ...
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the ...
The Motley Fool Canada2 个月
NASDAQ:VKTX (Viking Therapeutics)
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian ...